IR@PKUHSC  > 北京大学第一临床医学院  > 临床药理研究所
学科主题临床医学
The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers
Xiao, Y.1; Lv, Y.1; Zhang, X.2; Guo, Y.2; Bergstrom, T.3
关键词varenicline smoking cessation pharmacokinetics tolerability Chinese
刊名INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
2009-04-01
47期:4页:246-254
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]RECEPTOR PARTIAL AGONIST ; SMOKING-CESSATION ; DOSE PHARMACOKINETICS ; GLOBAL MORTALITY ; IN-VITRO ; SMOKERS ; NICOTINE ; SINGLE ; VIVO
英文摘要

Objective: Varenicline is a selective, nicotinic alpha(4)beta(2) acetylcholine receptor partial agonist that has been licensed as a smoking cessation drug in more than 70 countries worldwide. The current study was conducted in order to evaluate its pharmacokinetic (PK) properties and tolerability in healthy volunteer Chinese smokers. Methods: This was an open-label, non-randomized study conducted over 17 days at a single center in China. Male and female subjects (18 45 years old) received a single, 1 mg dose of varenicline on days 1 and 10 as well as 1 mg varenicline twice daily (12-h dosing interval) on Days 4 - 9. Results: A total of 14 subjects (50% male) received varenicline as per study protocol for 8 days. The mean maximum plasma concentration of varenicline (C(max)) was 1.93-fold larger at steady state (reached on Day 8, after 4 days of repeat dosing) than following a single dose, showing accumulation of varenicline on repeat administration. Median values of t(max) (time of occurrence of C(max)) were similar for both dosing regimens (3.0 and 2.5 h following single and multiple dosing, respectively). The mean elimination half-life following single and multiple dosing was 15.2 and 18.3 h, respectively. There was no evidence of time- or concentration-dependence in the PK of varenicline upon repeat dosing as the ratio of the area under the plasma concentration vs time curve (AUC) from time 0 - 12 h at steady state to the AUC from time 0 - 8 on Day I was nearly 1. The 2-sided 95% confidence intervals for this comparison included 1, demonstrating the linearity of the PK of varenicline for the single and multiple doses. Varenicline was safe and well-tolerated, adverse events were mild in severity and there were no abnormal laboratory tests. Conclusions: Varenicline I mg twice daily was safe and well-tolerated in a cohort of healthy male and female, 18- to 45-year-old Chinese smokers and demonstrated PK properties that were stable and reproducible and similar to those observed previously in Western subjects.

语种英语
WOS记录号WOS:000265163000004
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64347
专题北京大学第一临床医学院_临床药理研究所
作者单位1.Pfizer Pharmaceut Ltd, Beijing, Peoples R China
2.Pfizer Inc, New York, NY USA
3.Peking Univ, Hosp 1, Inst Clin Pharmacol, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Xiao, Y.,Lv, Y.,Zhang, X.,et al. The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS,2009,47(4):246-254.
APA Xiao, Y.,Lv, Y.,Zhang, X.,Guo, Y.,&Bergstrom, T..(2009).The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers.INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS,47(4),246-254.
MLA Xiao, Y.,et al."The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers".INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 47.4(2009):246-254.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xiao, Y.]的文章
[Lv, Y.]的文章
[Zhang, X.]的文章
百度学术
百度学术中相似的文章
[Xiao, Y.]的文章
[Lv, Y.]的文章
[Zhang, X.]的文章
必应学术
必应学术中相似的文章
[Xiao, Y.]的文章
[Lv, Y.]的文章
[Zhang, X.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。